Strattera-Induced Suicidality

Strattera is the one ADHD treatment that has received a black-box warning concerning increased suicidality. After a review and analysis of 13 clinical trials conducted with children, all but one for the treatment of ADHD, the FDA (2005c) identified an increased risk of suicidal thinking for Strattera. The bold black-box warning included in the label can be found in the 2007 Physicians Desk Reference  

Suicidal ideation in Child and Adolescents—STRATTERA (atomoxetine) increased the risk of suicidal ideation in short-term studies in children or adolescents with Attention-Deficit Hyperactivity Disorder (ADHD). Anyone considering the use of STRATTERA in a child or adolescent must balance this risk with the clinical needs. Patients who are started on therapy should be monitored closely for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in behavior. 

Once again, Eli Lilly has managed to promote one of its drugs as especially safe, when it is in fact especially dangerous. 

---